Open an account

Bionano Genomics

BNGO · NASDAQ

$1.25+$0.025 (+2.05%)TodayMarket closed ·
Prev close $1.22

About BNGO

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The company is headquartered in San Diego, California and currently employs 95 full-time employees. The company went IPO on 2018-08-01. The firm offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. The company also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The firm additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The firm markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).

Employees
95
Headquarters
San Diego, California
Listed
Aug 1, 2018
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
bionano.com

BNGO key statistics

Market cap
14.66M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
401.29K
Volume
433.17K
Open price
$1.21
High today
$1.32
Low today
$1.21
52 Week high
$2.23
52 Week low
$1.00

Bionano Genomics (BNGO) at a glance

As of Oct 20, 2026, Bionano Genomics (BNGO) shares are priced at $1.25, giving the company a market cap of 14.66M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.21 and $1.32. The current price is 2.9% above the day's low and 5.7% below its high.

Volume so far is 433.17K shares, in line with the average of 401.29K shares a day.

Over the past year Bionano Genomics has ranged from $1.00 to $2.23, and now sits 20% of the way up that range.

Bionano Genomics met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.64 per share against an estimate of -$0.6987.

The average analyst price target is $5.10, 309.6% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $5.10
Low
$4.04
Now
$1.25
High
$6.30

BNGO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 37.0% on average.

  1. Q3 FY24: reported -$24.00 per share against an estimate of -$12.85
  2. Q4 FY24: reported -$15.83 per share against an estimate of -$6.12
  3. Q1 FY25: reported -$1.15 per share against an estimate of -$3.08
  4. Q2 FY25: reported -$1.99 per share against an estimate of -$2.46
  5. Q3 FY25: reported -$1.59 per share against an estimate of -$1.95
  6. Q4 FY25: reported -$0.03 per share against an estimate of -$1.43
  7. Q1 FY26: reported -$0.76 per share against an estimate of -$0.8976
  8. Q2 FY26: reported -$0.64 per share against an estimate of -$0.6987

BNGO news

  • Henry Khederian

    Bionano Genomics Stock Surges Tuesday: What's Going On?

  • Avi Kapoor

    Crude Oil Rises Over 2%; Bionano Genomics Shares Plunge

  • Avi Kapoor

    Dow Falls Over 100 Points; US Retail Sales Top Estimates

  • A Preview Of Bionano Genomics's Earnings

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • A Glimpse of Bionano Genomics's Earnings Potential

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • What's Next: Bionano Genomics's Earnings Preview

Similar companies

Companies in the same industry as Bionano Genomics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.